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Introduction: Premature ovarian failure is defined as the cessation of ovarian activity before the age of 40 years. It
is biochemically characterized by low levels of gonadal hormones (estrogens and inhibins) and high levels of
gonadotropins (luteinizing hormone and follicle-stimulating hormone).
Case presentation: Our patient, a 22-year-old Caucasian woman under evaluation for infertility, had experienced
secondary amenorrhea from the age of 18. No positive family history was noted regarding premature menopause.
An examination of our patient’s karyotype showed the presence of a reciprocal translocation, apparently balanced,
which had the X chromosome long arm (q13) and the 14 chromosome short arm (p12) with consequent
karyotype: 46, X, t(X; 14)(q13;p12).
Conclusions: Our study has underlined that karyotyping is one of the fundamental investigations in the evaluation
of amenorrhea. It highlighted a genetic etiology, in the form of a chromosomal abnormality, as the causal factor in
amenorrhea.Introduction
Premature ovarian failure (POF) is defined by the cessa-
tion of ovarian activity before the age of 40 years [1].
This condition is biochemically characterized by low
levels of gonadal hormones (estrogens and inhibins) and
high levels of gonadotropins (luteinizing hormone (LH)
and follicle-stimulating hormone (FSH)) [2].
POF is considered idiopathic [3] in two thirds of cases,
with the patient having a normal karyotype; in the
remaining third of cases, it is secondary to genetic anom-
alies [4], autoimmune pathologies [5], pharmacological
therapies [6], radiotherapy, or surgical oophorectomy.
In the absence of surgical oophorectomy, chemotherapy
or pelvic radiation, POF encompasses a heterogeneous
spectrum of conditions through two major mechanisms,
follicle dysfunction and follicle depletion [7]. Although
there are many other reasons for ovarian failure, genetic* Correspondence: ducati98@libero.it
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reproduction in any medium, provided the oror chromosomal causes are the most important as their
presence affects subsequent management.
Our study emphasizes that karyotyping is one of the fun-
damental investigations in the evaluation of amenorrhea. It
highlights a genetic etiology, in the form of a chromosomal
abnormality, as the causal factor in amenorrhea.
Case presentation
Our patient, a 22-year-old Caucasian woman under
evaluation for infertility, had experienced secondary
amenorrhea from the age of 18 years. She had received
hormonal replacement for the past two years, which
resulted in cyclical bleeding, but she remained anovula-
tory. No positive family history was noted regarding pre-
mature menopause.
Pelvic ultrasonography showed the presence of an
anteflexed uterus, with a normal profile, echostructure
and dimensions. Her endometrium had a normal echo-
graphic aspect. Both her right and left ovary were nor-
mal with respect to dimension and form, without any
liquid effusion. A hysterosalpingogram confirmed the
normal uterus-tubal anatomy.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypophysis using paramagnetic contrast showed that her
sellar cavity had regular morphology and dimensions,
without any structural alterations. The adenohypophysis
was devoid of alterations. Her hypophyseal peduncle
oriented normally. Serum anti-ovarian and anti-adrenal
antibodies were absent. As it is possible to see from the
Table 1, our patient had high levels of gonadotropins
(LH: 41.17IU/L and FSH: 79.90IU/L; hypergonadotropic
amenorrhea) [2]. Her thyroid-stimulating hormone, free
tri-iodothyronine and free thyroxin hormone levels were
normal, while the levels of anti-thyroid peroxidase
antibodies and anti-thyroglobulin antibodies were very
high.
It was necessary, at this point, to conclude the diag-
nostics by studying her karyotype. Her karyotype was
obtained from T lymphocytes extracted from peripheral
blood using the common culture technique. The
obtained chromosomes were banded with Q-banding
methods using quinacrine. An examination of her karyo-
type revealed the presence of a mutual translocation, ap-
parently balanced, that involved the X chromosome long
arm (q13) and the 14 chromosome short arm (p12), with
consequent karyotype 46,X,t(X;14)(q13;p12) (Figure 1).
Breakpoints were confirmed with fluorescent in situ
hybridization (Figure 2, Table 2). To evaluate the inacti-
vation of the X chromosome, we used the human andro-
gen receptor (HUMARA) assay, which uses the locus of
the androgen receptor in Xq11.2. In the first exon of the
gene there was a highly polymorphic tri-nucleotide repe-
tition (CAG) next to the cleavage sites of restriction
enzymes sensitive to methylation (HpaII or HhaI),
methylated only on the inactive X chromosome. The
assay demonstrated that the active X chromosome was
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aOutside of normal range.To assess whether this was a de novo or a segregating
chromosomal abnormality, we studied the karyotype of
both parents. Their karyotypes were normal, implying
that the chromosomal abnormality was de novo. Further-
more, our patient did not present clinical manifestations
associated with X-linked recessive diseases.
Discussion
X-autosome translocations are extremely rare (one in
30,000). In women, one of the X chromosomes is inactive,
and this inactivation is completely random. This
phenomenon is called lyonization. In cases of X-
autosome translocation, the inactivation is not random
but involves the none-translocated X chromosome [9,10].
We must consider that the X-inactivation center in the
Xq13 area is turned off in the translocated chromosome,
and different genes, which are important for the develop-
ment and/or the functionality of the ovary, are present on
the long arm of chromosome X [11].We can assume that
X-autosome translocations do not interrupt the genes
involved in ovarian functionality, but that they cause
altered expression, because of their ‘position effect’ [12].
In females with an active X chromosome translocated
in all cells and with the breakpoint not interrupting any
functional gene, about half have ovarian failure (break-
points within the Xq13 to q26 region) and the other half
have a normal phenotype (breakpoints outside the Xq13
to q26 region) [13-15].
Conclusions
The purpose of this therapy was not only to intervene
in her climacteric symptoms, but to realize at the
same time primary and/or secondary prevention of
osteoporosis, cardiovascular pathology and cerebral in-
volutional pathologies.Result Normal range
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Figure 1 Karyotype 46, X, t(X; 14)(q13;p12).
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Figure 2 BAC clones used for fluorescent in situ hybridization with the relative position on the X chromosome. In the two images you
see the signs of the clones which define the breakpoint on X. Also see Table 2.
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the fundamental investigations in the evaluation of
amenorrhea. It has highlighted a genetic etiology for
amenorrhea in the form of a chromosomal abnormality.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanyingTable 2 BAC clones used for fluorescent in situ
hybridization with its location on the X chromosome
Clone Band Position FISH resolution
RP11-450P7 Xp11.1 chrX:21,533,785-21,657,970 derX
RP11-21E13 Xp11.1 chrX:57,294,374-57,500,705 derX
RP11-63004 Xq13.3 chrX:73,819,700-73,985,772 derX
RP11-91J20 Xq13.3 chrX:74,412,682-74,572,432 derX
RP11-194N18 Xq13.3 chrX:75,606,737-75,754,256 der14
RP11-28L16 Xq21.1 chrX:76,249,350-76,405,210 der14
RP11-19G6 Xq21.1 chrX:77,789,620-77,954,427 der14
RP11-91G23 Xq21.1 chrX:79,149,705-79,309,977 der14
RP11-336F4 Xq21.1 chrX:83,463,633-83,463,726 der14
RP11-210I11 Xq21.31 chrX:90,459,260-90,599,859 der14
RP11-138B3 Xq22.1 chrX:98,535,557-98,698,689 der14
RP11-265K3 Xq28 chrX:154,603,527-154,763,828 der14
The clones can be displayed on the site of the University of California, Santa
Cruz [8]. FISH: fluorescent in situ hybridization.images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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